What are the indications, dosing regimen, contraindications, adverse effects, and monitoring recommendations for sulindac?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sulindac: Clinical Overview

Indications

Sulindac is FDA-approved for acute or long-term treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis 1. The drug should be used at the lowest effective dose for the shortest duration consistent with treatment goals 1.

Key Indication Details:

  • Not recommended for rheumatoid arthritis patients classified as ARA Functional Class IV (largely bedridden or wheelchair-bound) 1
  • Demonstrated comparable effectiveness to aspirin 2400-4800 mg daily in osteoarthritis and rheumatoid arthritis trials 1
  • Can be combined with gold salts in rheumatoid arthritis for additional symptomatic relief 1

Dosing Regimen

The standard dosing is 200-400 mg daily in divided doses (twice daily administration) 1, 2.

Condition-Specific Dosing:

  • Osteoarthritis/Rheumatoid Arthritis: 200-400 mg daily 1
  • Ankylosing Spondylitis: 200-400 mg daily 1
  • Acute Painful Shoulder: 300-400 mg daily 1
  • Acute Gouty Arthritis: 400 mg daily 1

Special Populations:

  • Renal Insufficiency: Lower daily dosage required to avoid excessive drug accumulation; close monitoring mandatory 1
  • Hepatic Insufficiency: Reduced doses required; plasma concentrations of active sulfide metabolite are higher in alcoholic liver disease 1
  • Pediatric: Pharmacokinetics not established 1

Important: Higher doses (600 mg daily) showed no additional efficacy but increased adverse reactions, particularly gastrointestinal and blood chemistry abnormalities 3.


Contraindications

Sulindac is absolutely contraindicated in the following situations 1:

  • Known hypersensitivity to sulindac or its excipients
  • History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs (risk of severe, rarely fatal anaphylactic/anaphylactoid reactions)
  • Peri-operative pain in coronary artery bypass graft (CABG) surgery

Adverse Effects

Common Adverse Effects:

Gastrointestinal reactions are the most frequent, though sulindac demonstrates a lower incidence than aspirin 1:

  • Dyspepsia, abdominal pain, GI discomfort (10-20% prevalence) 4
  • Constipation (20-30% of cases, usually mild) 2
  • Rash and dizziness (transient, mild to moderate) 5

Serious Adverse Effects Requiring Vigilance:

Hepatotoxicity: Sulindac has more potential for hepatic complications than other NSAIDs 4. Serious multisystem reactions including fever, skin involvement, liver toxicity, CNS effects, lymphadenopathy, bone marrow suppression, and pulmonary involvement have been reported, including fatalities 6.

Renal Toxicity:

  • Causes small but significant reduction in creatinine clearance (37.0 to 34.7 ml/min/1.73m²) in patients with moderate chronic renal insufficiency 7
  • Reversible upon discontinuation 7
  • 2% of patients discontinue NSAIDs due to renal complications 4

Cardiovascular:

  • Mean blood pressure increase of 5 mm Hg 4
  • Avoid in congestive heart failure and use cautiously in hypertension 4

GI Bleeding:

  • Age-dependent risk: 1 in 2,100 for adults <45 years vs. 1 in 110 for adults >75 years 4
  • Risk increases 3-6 fold when combined with anticoagulants 4

Pregnancy: Avoid 6-8 weeks before term due to risk of prolonged pregnancy/labor and fetal antiplatelet effects 4


Monitoring Recommendations

Laboratory Monitoring:

  • Hepatic function: Monitor for transaminitis and synthetic impairment, particularly given sulindac's higher hepatotoxicity risk 4
  • Renal function: Essential in patients with renal insufficiency; expect reversible decreases in creatinine clearance 7
  • Complete blood count: Watch for bone marrow suppression in context of multisystem reactions 6

Clinical Monitoring:

  • Blood pressure: Monitor for hypertension exacerbation (mean increase 5 mm Hg) 4
  • INR: Expect up to 15% increase when combined with anticoagulants 4
  • GI symptoms: Assess for dyspepsia, bleeding risk factors 4
  • Multisystem toxicity: High fever, rash, organ involvement warrant immediate discontinuation 6

Risk Mitigation Strategies:

  • GI protection: Combine with PPI or H2 blocker for dyspepsia; use PPI or misoprostol for patients with prior GI bleeding history 4
  • Avoid in cirrhosis: Risk of hematologic and renal complications 4
  • Caution with concurrent medications: ACE inhibitors, beta blockers, anticoagulants all increase risk 4

Critical Pitfall:

Unlike some NSAIDs, sulindac does not appear to significantly alter prostaglandin excretion in short-term use at therapeutic doses in patients with moderate renal impairment 7, potentially offering advantages over other NSAIDs in this population when used cautiously with close monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.